GlobalData on MSN1d
Lilly touts Omvoh’s superiority over J&J’s Stelara in Crohn’s
Stelara is one of the most successful Crohn’s therapies, generating $10.8bn last year, Lilly hopes to introduce Omvoh as its ...
FiercePharma2d
Johnson & Johnson eases initial Stelara blows with strong Darzalex, Carvykti growth
Johnson & Johnson's immunology superstar Stelara and oncology blockbuster Darzalex have long been among the company's top ...
BioSpace2d
Lilly’s Omvoh Beats J&J’s Stelara in Head-to-Head Phase III Crohn’s Disease Trial
At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting ...
Managed Healthcare Executive2d
FDA Approves Imuldosa, the Fifth Stelara Biosimilar
Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.
Drug Store News2d
FDA approves Dong-A ST’s Stelara biosimilar
Imuldosa is used for the treatment of patients with autoimmune diseases such as plaque psoriasis, psoriatic arthritis, ...
FiercePharma3d
On road to crowded Crohn's disease market, Lilly's Omvoh bests J&J's Stelara in head-to-head study
On a mission to collect a key Crohn’s disease approval and build out its inflammatory bowel disease (IBD) profile, Eli Lilly ...
Tremfya, Carvykti sales grow as J&J prepares for Stelara patent loss
Biosimilar competition is expected in early January for the company’s second highest-selling drug, putting greater focus on ...
Medscape1d
FDA Approves Fifth Ustekinumab Biosimilar
The drug is approved for multiple inflammatory conditions and is expected to launch in the first half of 2025.
J&J quarterly earnings beat expectations, shows progress on talc liabilities
Johnson and Johnson reported stronger-than-expected third-quarter earnings, driven by surging sales of cancer medicine ...
GlobalData on MSN5d
South Korean company Dong-A ST wins FDA approval for Stelara biosimilar
Imuldosa is the latest FDA-approved biosimilar of J&J’s blockbuster therapy for the treatment of certain autoimmune diseases.
Cancer drug sales lift J&J past Wall Street expectations
Johnson & Johnson raised its 2024 profit and sales forecasts on Tuesday after reporting strong sales of oncology drugs and ...
Monthly Prescribing Reference1d
FDA Approves Stelara Biosimilar Imuldosa
The Food and Drug Administration (FDA) has approved Imuldosa ™ (ustekinumab-srlf), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases. Imuldosa, ...